Drugmaker Bristol-Myers Squibb announced Thursday a $74 billion deal to buy Celgene, in one of the biggest mergers in pharmaceutical industry history.

The drug giant has been an active partner in deals with North Carolina-based companies.

The deal, which still needs the approval of shareholders and regulators, will be paid with a combination of stock and cash. Bristol-Myers Squibb, which itself is the result of a 1989 merger of two companies that traced their roots back to the 19th century. Bristol-Myers Squibb is the eighth largest US drugmaker, with annual revenue of $20.8 billion in 2017. Celgene is the ninth largest with revenue of $13 billion.

Chapel Hill’s Cardioxyl gets potential $2 billion buyout deal from Bristol-Myers Squibb

TARGET PharmaSolutions teams with Bristol-Myers Squibb on IBD Study

The combined company could become the fourth largest pharmaceutical company in the United States.

Bristol would gain the cancer treatment Revlimid as well as inflammatory disease treatments and several products close to launching.

The combined company will have nine products with more than $1 billion in annual sales. Bristol Chairman and CEO Giovanni Caforio said in a prepared statement that the combination will create a deep product portfolio that drives growth.

Durham’s GeneCentric lands Bristol-Myers Squibb buy-in

It was a hard sell, however, in premarket trading Thursday. Shares of Bristol plunged more than 15 percent. Celgene soared 31 percent.

Under terms of the deal, shareholders of Celgene Corp., based in Summit, New Jersey, will receive one share of Bristol-Myers Squibb plus $50 in cash for each share they own. They’ll also receive one tradeable contingent value right for each Celgene share, allowing the holder to receive a payment when future regulatory milestones are hit.

The cash-and-stock portion of the deal total $102.43, based on Wednesday’s closing price of $52.43 for Bristol shares. That represents a premium of nearly 54 percent to Celgene’s closing price of $66.64.

Shareholders of Bristol-Myers Squibb Co., based in New York City, would own about 69 percent of the company, with Celgene shareholders owning about 31 percent.